GILD pulled back 3% today, underperforming the Nasdaq's 1% lift, but its 12‑month SMA remains above the 50‑day SMA, indicating an uptrend. Fundamentally, the company’s Q1 earnings beat expectations and its HIV and oncology pipelines continue to expand, supporting a bullish outlook.

Investor sentiment appears mixed after the recent dip, yet social media chatter and analyst commentary still highlight Gilead’s dominant HIV franchise. Broad market enthusiasm for biotech betting platforms like Kalshi adds a tailwind, keeping sentiment bullish.

The main risk is emerging competition in the HIV space and potential regulatory delays, which could curb short‑term gains. Nonetheless, Gilead’s diversified pipeline and strong cash flow suggest a resilient long‑term trajectory, keeping the outlook bullish.

Technical indicators show the 14‑day RSI at 32, entering oversold territory, while the MACD histogram turned positive, hinting at a near‑term bounce. The stock is trading just above the 200‑day moving average, a classic bullish signal, supporting a bullish stance.